Sequoia Capital leads $50m Series C in Chinese biotech startup Adagene

Sequoia Capital leads $50m Series C in Chinese biotech startup Adagene

Photo: Pixabay

Venture capital firm Sequoia Capital China has led the $50-million Series C fundraising round in Adagene, a Chinese antibody discovery and development firm based in Suzhou, according to an announcement.

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief
Subscribe to Newsletter